AgeneBio's Unattributed - II Round

AgeneBio raised a round of funding on July 28, 2016.

AgeneBio is developing therapies for people who have Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD). The company has a new clinical strategy to help address the therapeutic nee…

Articles about AgeneBio's Unattributed - II Round: